Skip to main content

Table 2 Results of base case cost-effectiveness analysis

From: Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran

Strategy Cost($) Incr Cost($)a Effb Incr Effc ICER($) Special
No screening 1455.07 0 7.40 0 0 Base line
SARC-F 1809.41 354.34 7.59 0.19 1897.84  
SARSA-Mod 3140.83 1685.76 8.30 0.90 1881.96  
MSRA 3151.27 1696.20 8.30 0.89 1898.33  
EWGSOP 3518.75 2063.68 8.50 1.10 1875.67  
  1. aIncremental costs, bEffectiveness, cIncremental Effectiveness
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us